mRNA-1195

BIOLOGICAL2 trials

Sponsors

ModernaTX, Inc.

Conditions

Epstein-Barr Virus InfectionMultiple Sclerosis

Phase 1

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

Active, not recruitingNCT05831111

ModernaTX, Inc.Epstein-Barr Virus Infection

Start: 2023-04-05End: 2026-10-13Updated: 2026-08-11

Phase 2

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

RecruitingNCT06735248

ModernaTX, Inc.Multiple Sclerosis

Start: 2025-04-16End: 2029-01-08Target: 180Updated: 2026-06-15